Hariprasad Vankayalapati

Hariprasad Vankayalapati M.Pharm., Ph.D.

Research Associate Professor
Applied Cancer Research and Drug Discovery

Hariprasad Vankayalapati M.Pharm., Ph.D.

Dr. Hari is currently serving as a Research Associate Professor of Medicinal Chemistry at the Applied Cancer Research and Drug Discovery Division of Translational Genomics Research Institute (TGen) in Phoenix, AZ since Oct 2017. His research focuses on early discovery, and to IND stage of development of small molecule targeted therapeutics particularly; targeting kinase signaling, immunokinases, epigenetics, nuclear hormone receptors, immune therapeutics - A target class in treating cancer, inflammation, autoimmune, and neurodegenerative diseases.

Prior to TGen, Dr. Hari was serving as Assistant Professor/Chief Scientist of Medicinal Chemistry at the Center for Investigational Therapeutics (CIT) of The Huntsman Cancer Institute (HCI) & School of Medicine of University Of Utah in Salt Lake City (Nov 2009 to Sep 2017). With a support from Huntsman Cancer Institute, Dr. Hari established a Medicinal. Organic, Computational Chemistry capabilities and successfully executed the translational research in search for novel cancer therapeutics. His researches at HCI lead to three spin-off Pharmaceutical companies and clinical stage three agents. From 2006-2009 Dr. Hari served as Chief Scientist at the SuperGen/Astex Pharmaceuticals (now Otsuka Pharmaceuticals). From 2003-2006 he was serving as program director of Medicinal Chemistry for early discovery, development and was key in creating several pipeline pre-clinical programs, CLIMB technology and co-founded Montigen Pharmaceuticals in year 2003. Later in year 2006 Montigen was acquired by SuperGen Inc., for 40 million where Dr. Hari played a key role in bringing science/technology in this deal transaction. Dr. Hari’s involvement over the years in Drug Discovery/Development, and his leadership lead to the discovery of first-in-class three clinical phase drug candidates; Amuvatinib/MP-470, SGI-1776 and SGI-110. 

In addition, Dr. Hari is also serving as Chief Scientific Officer of Arrien Pharmaceuticals, Oncolexis Therapeutics and a scientific advisor for few startup Pharmaceutical companies. He is an author of more than 70 peer reviewed scientific publications & presentations in Medicinal, Organic, Computational Chemistry and drug discovery areas. He is an inventor of over 23 published/issued US/WO patents. He holds PhD. and M. Pharm degrees in Medicinal Chemistry from the Institute of Chemical Technology (formally UDCT) of University of Mumbai and University of Karnatk in India. He completed his Post-Doctoral training in Organic Chemistry from University of Sunderland in England and Medicinal Chemistry with Prof. Laurence H. Hurley from University of Arizona Cancer Center in Tucson, USA.


PUBLICATIONS

Repurposing of Proton Pump Inhibitors as First Identified Small Molecule Inhibitors of Endo-β-N-acetylglucosaminidase (ENGase) for the Treatment of Rare NGLY1 Genetic Disease. Bi Y, Might M, Vankayalapati H, Kuberan B. Bioorg Med Chem Lett. (2017). 

Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime beta-Catenin Pathway Inhibitors. Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S (2015). J Med Chem, 58(15), 5854-62.

Inhibition of Nek2 by small molecules affects proteasome activity. Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ (2014). Biomed Res Int, 2014, 273180.

High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S (2013). J Med Chem, 56(23), 9496-508.

Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents. Xu Y, Brenning B, Clifford A, Vollmer D, Bearss J, Jones C, McCarthy V, Shi C, Wolfe B, Aavula B, Warner S, Bearss DJ, McCullar MV, Schuch R, Pelzek A, Bhaskaran SS, Stebbins CE, Goldberg AR, Fischetti VA, Vankayalapati H (2013). ACS Med Chem Lett, 4(12), 1142-1147.

A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K, Prchal JT (2013). J Mol Med (Berl), 91(4), 507-12.

Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis. Basham KJ, Kieffer C, Shelton DN, Leonard CJ, Bhonde VR, Vankayalapati H, Milash B, Bearss DJ, Looper RE, Welm BE (2013). J Biol Chem, 288(4), 2261-70.

Use of a bacteriophage lysin to identify a novel target for antimicrobial development. Schuch R, Pelzek AJ, Raz A, Euler CW, Ryan PA, Winer BY, Farnsworth A, Bhaskaran SS, Stebbins CE, Xu Y, Clifford A, Bearss DJ, Vankayalapati H, Goldberg AR, Fischetti VA (2013). PLoS One, 8(4), e60754.

Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Gaza Strip Palestinians. Sirdah M, Reading NS, Vankayalapati H, Perkins SL, Shubair ME, Aboud L, Roper D, Prchal JT (2012). Blood Cells Mol Dis, 49(3-4), 152-8.

Innovative therapy for Classic Galactosemia - Tale of two HTS. Tang M, Odejinmi SI, Vankayalapati H, Wierenga KJ, Lai K. (2012). Mol Genet Metab, 105(1), 44-55.

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ (2011). ACS Med Chem Lett, 2(12), 907-912.

Identification of novel small molecule inhibitors of 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) kinase of Gram-negative bacteria. Tang M, Odejinmi SI, Allette YM, Vankayalapati H, Lai K (2011). Bioorg Med Chem, 19(19), 5886-95.

Structure-activity analysis and cell-based optimization of human galactokinase inhibitors. Odejinmi S, Rascon R, Tang M, Vankayalapati H, Lai K (2011). ACS Med Chem Lett, 2(9), 667-672.

Targeting Axl and Mer Kinases in Cancer. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S (2011). Mol Cancer Ther, 10(10), 1763-1773.

Back To Top